Copeptin and adrenomedullin in a large cohort of patients with coronary heart disease and newly diagnosed glucose intolerance (“Silent diabetes study”)

Aims: Copeptin is used as a diagnostic marker for acute myocardial infarction, adrenomedullin as a prognostic marker for congestive heart failure. Both hormones may be involved in pathophysiology of metabolic syndrome. Methods: We have used sera of the “Silent diabetes study” (1). Sera of 920 patients were eligible for this analysis, 777 of patients with elective coronary angiography, 143 with a acute coronary syndrome. All patients underwent an orale glucose tolerance test, patients with previous known diabetes were excluded. In coronary angiography, 59 patients had no coronary disease (no CHD), 152 patients ha…